236 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
in the field of retinitis pigmentosa and/or any other disease in ophthalmology.
We will be primarily responsible for the design and implementation of clinical … development of KIO-301 through phase 2, for which we will be reimbursed by TOI subject to a maximum amount. TOI will be responsible at its own cost
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
). In addition, functional MRI measures showed reactivation of the specific regions of the brain responsible for vision.
Held a Type B, pre-IND meeting
8-K
EX-99.1
pqoob
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-4.1
3sj92ps224sjkfyjl1fn
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.2
b6j65ag
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.3
mq8sobp3mziu521
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
h5dlb53 q80gvtv
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
ndeh6pdk2y2fsmu
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
thtpuaa
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
ch1d e8yth3ndfpd
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm